Compare ACGL & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACGL | RMD |
|---|---|---|
| Founded | 2001 | 1989 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4B | 33.6B |
| IPO Year | 1996 | 1996 |
| Metric | ACGL | RMD |
|---|---|---|
| Price | $107.38 | $236.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 20 |
| Target Price | $113.00 | ★ $265.11 |
| AVG Volume (30 Days) | ★ 2.2M | 1.3M |
| Earning Date | 10-27-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 1.10% |
| EPS Growth | 3.66 | ★ 9.67 |
| EPS | ★ 8.89 | 2.92 |
| Revenue | ★ $19,929,000,000.00 | $2,957,013,000.00 |
| Revenue This Year | N/A | $3.23 |
| Revenue Next Year | N/A | $6.40 |
| P/E Ratio | ★ $12.45 | $82.37 |
| Revenue Growth | ★ 14.27 | 13.44 |
| 52 Week Low | $87.05 | $180.27 |
| 52 Week High | $110.73 | $277.67 |
| Indicator | ACGL | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 46.51 |
| Support Level | $93.23 | $217.41 |
| Resistance Level | N/A | $236.06 |
| Average True Range (ATR) | 2.43 | 7.64 |
| MACD | 0.71 | -2.01 |
| Stochastic Oscillator | 58.98 | 33.47 |
Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.